TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05523947: Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

Sponsor: Yuhan Corporation · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 147 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$2,591,820

Rescue Site Savings

+$1,727,880

Unlock Full NCT05523947 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05523947 Rescue Dossier →